Kidney Disease

An increase in alpha-globin gene copy number was associated with a greater prevalence of chronic kidney disease and incidence of end-stage kidney disease in Black Americans, according to published data.

An analysis of data showed patients with chronic kidney disease and type 2 diabetes who were or were not prescribed mineralocorticoid receptor antagonists saw reductions in major adverse kidney outcomes after taking dapagliflozin.

The American Kidney Fund convened at a working session summit to discuss key goals, progress and upcoming steps for the Unknown Causes of Kidney Disease Project, according to an American Kidney Fund press release.

Researchers successfully used electronic health record data to measure and identify risk factors of chronic kidney disease progression in a large cohort of pediatric patients, according to a speaker at ASN Kidney Week.

When treated with direct-acting antiviral therapy, patients with chronic hepatitis C virus infection were at a lower risk for end-stage kidney disease and the composite of ESKD or death, according to a speaker at ASN Kidney week.

The “strong associations” of urine-to-plasma ratios with cardiovascular mortality implies a connection between renal clearance of uremic solutes and CVD pathogenesis, according to a speaker from ASN Kidney Week.

Discrepancies between eGFR and measured GFR suggest that measured GFR may be the superior calculator for diagnosing kidney disease, according to a speaker at ASN Kidney Week.

A new risk equation called The Kidney Disease Risk Equation uses six variables to predict the onset of chronic kidney disease within 5 years, and it can be added into existing health care systems, according to a speaker at ASN Kidney Week.

There was no significant difference in results when giving finerenone with or without sodium-glucose cotransporter-2 inhibitors to patients with type 2 diabetes and chronic kidney disease, according to a speaker at ASN Kidney Week.

The oral anemia drug daprodustat showed noninferiority to erythropoiesis-stimulating agents for achieving targeted hemoglobin levels and cardiovascular risk in patients with kidney disease on dialysis and not on dialysis, according to phase 3 data presented at ASN Kidney Week.